The clinical, histologic, and immunopathological findings of three young Japanese males with congenital C9 deficiency and primary IgA nephropathy are reported. The C9 deficiency was discovered either through mass complement screening, or when low hemolytic activity for CH50 and normal C3 levels were detected in plasma. Hematuria and proteinuria were detected at the age of 8 or 9 years as a result of annual urinary screening tests for school children. Renal biopsy showed focal and segmental mesangial proliferation with small epithelial crescents in one patient, and mild, diffuse mesangial proliferation in two. IgA and C3 were deposited predominantly in the mesangial area, and staining for C9 was negative in these patients. Electron microscopy revealed electron dense deposits predominantly in mesangial and paramesangial zones. Immunohistochemical staining in renal biopsy tissues from two patients showed mesangial staining for C5, C8, and S-protein, but staining for C5b-9 neoantigen was completely negative. These results show that the formation of C5b-9 complex is not essential for the induction of human IgA nephropathy, and also for the proliferation of mesangial and even parietal epithelial cells.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1038/ki.1992.412 | DOI Listing |
Gut Microbes
December 2025
State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, China.
IgA nephropathy (IgAN) is related to the balance of gut microbiota. However, it is unclear whether changes in the gut microbiota can cause IgAN or attenuate its progression. This study employed IgAN and human microbiota-associated (HMA)-IgAN models to investigate the impact of IgAN on gut microbiota alteration and the mechanisms by which gut microbiota might trigger IgAN.
View Article and Find Full Text PDFClin Kidney J
January 2025
Department of General Internal Medicine and Nephrology, Robert Bosch Hospital Stuttgart, Stuttgart, Germany.
Background: Sparsentan, a dual-acting antagonist for both the angiotensin II receptor type 1 and the endothelin receptor type A, has emerged as a promising therapeutic agent for the treatment of IgA nephropathy (IgAN). Following the publication of the PROTECT trial, sparsentan recently received approval for the treatment of IgAN in Europe. However, it remains uncertain whether an additive effect can be observed in the context of existing treatment with sodium-glucose co-transporter 2 (SGLT2) inhibitors, given that the PROTECT study did not investigate this dual therapy approach.
View Article and Find Full Text PDFIndian J Nephrol
October 2024
UOC Nefrologia Dialisi e Trapianto, IRCCS Istituto Giannina Gaslini, Largo Gerolamo Gaslini, Genova, Italy.
Indian J Nephrol
August 2023
Department of Nephrology, Zydus Hospital, Ahmedabad, Gujarat, India.
Fibrillary and immunotactoid glomerulonephritis represent the pathological entities characterized by structured fibrillary/microtubular deposits, whose identification is possible only by electron microscopy. We report a 46-year-old female who presented with proteinuria 15 years after the onset of psoriasis. Diffuse global glomerulosclerosis pattern was noted on light microscopy.
View Article and Find Full Text PDFMed J Armed Forces India
July 2023
Resident (Nephrology), Army Hospital (R&R), Delhi Cantt, India.
Sarcoidosis is a multisystem granulomatous disease of unknown etiology, characterized by noncaseating epithelioid granuloma, multinucleate giant cells, and tissue destruction. While lung and lymph node involvement is common, isolated renal involvement is rare. We report the case of a 55-year-old female patient, with renal limited sarcoidosis, who presented with worsening sensorium and acute kidney injury.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!